Associated Papers
Clinical Manifestations of VEXAS Syndrome Across a Broad Spectrum of UBA1 Mutation Burden.
Anderson M et al.
Arthritis & Rheumatology (hoboken, N.j.), 2026
Characterizing VEXAS syndrome in women: Findings from an international multicenter study.
Bourguiba R et al.
Journal of Internal Medicine, 2025
Rapid clinical deployment of UBA1 testing in patients with VEXAS syndrome.
Wadsworth PA et al.
American Journal of Clinical Pathology, 2025
Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network.
Vitale A et al.
Frontiers in Pharmacology, 2025
Promise of Jak Inhibition in the Management of VEXAS, Case Report with Review of the Literature.
Alnahas Z et al.
Open Access Rheumatology : Research and Reviews, 2025
VEXAS syndrome in rheumatology practice: features from a multicenter cohort in north-east Italy.
Bindoli S et al.
Frontiers in Immunology, 2025
Clinical characteristics, disease trajectories and management of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a systematic review.
Kouranloo K et al.
Rheumatology International, 2024
Expanding the VEXAS diagnostic workup: the role of peripheral blood cytological analysis.
Baggio C et al.
Frontiers in Immunology, 2024
VEXAS-Syndrome, a newly described autoinflammatory systemic disease with dermatologic manifestations.
Baur V et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg, 2023
Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.
Beck DB et al.
Jama, 2023
Select a paper to view details